Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:1347:135-162.
doi: 10.1007/5584_2021_639.

Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges

Affiliations

Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges

Sevil Köse et al. Adv Exp Med Biol. 2021.

Abstract

Lysosomal storage disorders (LSDs) are rare inborn errors of metabolism caused by defects in lysosomal function. These diseases are characterized by accumulation of completely or partially degraded substrates in the lysosomes leading to cellular dysfunction of the affected cells. Currently, enzyme replacement therapies (ERTs), treatments directed at substrate reduction (SRT), and hematopoietic stem cell (HSC) transplantation are the only treatment options for LSDs, and the effects of these treatments depend strongly on the type of LSD and the time of initiation of treatment. However, some of the LSDs still lack a durable and curative treatment. Therefore, a variety of novel treatments for LSD patients has been developed in the past few years. However, despite significant progress, the efficacy of some of these treatments remains limited because these therapies are often initiated after irreversible organ damage has occurred.Here, we provide an overview of the known effects of LSDs on stem cell function, as well as a synopsis of available stem cell-based cell and gene therapies that have been/are being developed for the treatment of LSDs. We discuss the advantages and disadvantages of use of hematopoietic stem cell (HSC), mesenchymal stem cell (MSC), and induced pluripotent stem cell (iPSC)-related (gene) therapies. An overview of current research data indicates that when stem cell and/or gene therapy applications are used in combination with existing therapies such as ERT, SRT, and chaperone therapies, promising results can be achieved, showing that these treatments may result in alleviation of existing symptoms and/or prevention of progression of the disease. All together, these studies offer some insight in LSD stem cell biology and provide a hopeful perspective for the use of stem cells. Further development and improvement of these stem cell (gene) combination therapies may greatly improve the current treatment options and outcomes of patients with a LSD.

Keywords: Gene therapy; Hematopoietic stem cell; Induced pluripotent stem cell; Lysosomal storage disease; Lysosomal storage disorder; Mesenchymal stem cell; Neural stem cell; Stem cell.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S et al (2016) A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with gaucher disease and parkinsonism. J Neurosci 36(28):7441–7452 - PubMed - PMC
    1. Ahmad I, Hunter RE, Flax JD, Snyder EY, Erickson RP (2007) Neural stem cell implantation extends life in Niemann-Pick C1 mice. J Appl Genet 48(3):269–272 - PubMed
    1. Aldenhoven M, Kurtzberg J (2015) Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions. Cytotherapy 17(6):765–774 - PubMed
    1. Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC et al (2014) Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. Bone Marrow Transplant 49(8):1016–1021 - PubMed
    1. Audesse AJ, Webb AE (2018) Enhancing Lysosomal Activation Restores Neural Stem Cell Function During Aging. J Exp Neurosci 12:1179069518795874 - PubMed - PMC

LinkOut - more resources